Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs IPCA LABS - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA IPCA LABS CIPLA/
IPCA LABS
 
P/E (TTM) x 36.3 27.4 132.7% View Chart
P/BV x 4.2 8.5 49.4% View Chart
Dividend Yield % 0.5 0.1 341.8%  

Financials

 CIPLA   IPCA LABS
EQUITY SHARE DATA
    CIPLA
Mar-20
IPCA LABS
Mar-19
CIPLA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs5861,042 56.2%   
Low Rs357590 60.5%   
Sales per share (Unadj.) Rs207.0298.6 69.3%  
Earnings per share (Unadj.) Rs18.635.0 53.1%  
Cash flow per share (Unadj.) Rs33.249.4 67.1%  
Dividends per share (Unadj.) Rs4.003.00 133.3%  
Dividend yield (eoy) %0.80.4 230.9%  
Book value per share (Unadj.) Rs195.5247.1 79.1%  
Shares outstanding (eoy) m806.35126.35 638.2%   
Bonus/Rights/Conversions ESOSESOS-  
Price / Sales ratio x2.32.7 83.3%   
Avg P/E ratio x25.323.3 108.7%  
P/CF ratio (eoy) x14.216.5 86.1%  
Price / Book Value ratio x2.43.3 73.0%  
Dividend payout %21.58.6 250.9%   
Avg Mkt Cap Rs m379,912103,108 368.5%   
No. of employees `00025.813.4 192.3%   
Total wages/salary Rs m30,2707,874 384.4%   
Avg. sales/employee Rs Th6,459.62,807.0 230.1%   
Avg. wages/employee Rs Th1,171.2585.8 199.9%   
Avg. net profit/employee Rs Th580.2329.0 176.4%   
INCOME DATA
Net Sales Rs m166,94937,732 442.5%  
Other income Rs m3,442577 596.7%   
Total revenues Rs m170,39138,309 444.8%   
Gross profit Rs m32,0606,901 464.6%  
Depreciation Rs m11,7471,824 643.9%   
Interest Rs m1,974189 1,045.9%   
Profit before tax Rs m21,7825,465 398.6%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3121,042 605.5%   
Profit after tax Rs m14,9954,422 339.1%  
Gross profit margin %19.218.3 105.0%  
Effective tax rate %29.019.1 151.9%   
Net profit margin %9.011.7 76.6%  
BALANCE SHEET DATA
Current assets Rs m117,03823,778 492.2%   
Current liabilities Rs m43,93110,975 400.3%   
Net working cap to sales %43.833.9 129.1%  
Current ratio x2.72.2 123.0%  
Inventory Days Days96104 92.2%  
Debtors Days Days8566 129.0%  
Net fixed assets Rs m107,42420,368 527.4%   
Share capital Rs m1,613253 638.1%   
"Free" reserves Rs m156,01830,971 503.8%   
Net worth Rs m157,63031,224 504.8%   
Long term debt Rs m23,6931,409 1,682.1%   
Total assets Rs m236,62645,507 520.0%  
Interest coverage x12.030.0 40.2%   
Debt to equity ratio x0.20 333.2%  
Sales to assets ratio x0.70.8 85.1%   
Return on assets %7.210.1 70.8%  
Return on equity %9.514.2 67.2%  
Return on capital %12.817.3 74.1%  
Exports to sales %33.045.9 72.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs m55,17517,308 318.8%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m56,03617,308 323.8%   
Fx outflow Rs m6,7646,266 107.9%   
Net fx Rs m49,27211,042 446.2%   
CASH FLOW
From Operations Rs m30,6854,923 623.3%  
From Investments Rs m1,040-1,563 -66.6%  
From Financial Activity Rs m-29,488-1,832 1,609.6%  
Net Cashflow Rs m2,3401,528 153.2%  

Share Holding

Indian Promoters % 16.0 45.9 34.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 11.4 107.0%  
FIIs % 23.7 25.3 93.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.4 150.6%  
Shareholders   161,166 36,892 436.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  NOVARTIS  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 15, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS